CTI BioPharma Net Tangible Assets

CTI BioPharma (CTIC) currently reports a net tangible assets of $-25M as of March 2023. That compares with $-53M in the prior-year period — up 51.9% year over year. Use the charts on this page to explore CTI BioPharma's net tangible assets history and peer comparisons.

CTI BioPharma's net tangible assets increased from $-53M to $-25M — a 51.9% year-over-year increase (period ending March 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

CTI BioPharma reported $-25M in net tangible assets as of March 2023. That compares with $-53M in the prior-year period — up 51.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net tangible assets of $-25M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for CTI BioPharma, and consider following CTIC for alerts when major investors trade the stock.

CTI BioPharma is classified in the Healthcare sector. On net tangible assets, it currently shows $-25M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CTIC with unrelated industries.